European Medicines Agency issues opinion that the benefits of deonosumab do not outweigh its risks in patients with castration-resistant prostate cancer at high risk of spreading to the bones

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has finalised its assessment of an application to extend the use of denosumab (Xgeva) to include the treatment of patients with castration-resistant prostate cancer at high risk of spreading to the bones. The CHMP was of the opinion that the benefits of Xgeva had not been shown to outweigh its risks in these patients. Read more here.